Mindmed announces voluntary delisting from cboe canada

New york--(business wire)---- $mnmd--mind medicine (mindmed) inc. (nasdaq: mnmd) (cboe canada: mmed) (the “company” or “mindmed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has elected to voluntarily delist its common shares from cboe canada, effective at the close of markets on april 10, 2024, and the notice of voluntary delisting has been accepted by cboe canada. mindmed's common shares will continue to be lis.
MNMD Ratings Summary
MNMD Quant Ranking